title: CRF antagonists Dupont.
abstract: DuPont (formerly DuPont Merck), Neurocrine Biosciences and Cephalon are conducting a joint investigation into corticotropin releasingfactor (CRF) ligands. These compounds may have potential as antidepressants and anxiolytics. SV-030 and other analogs from the series are entering preclinical development [361291], [362064].
authors.affiliation: Genneruxi Medical Center, Cagliari, Italy. apreti@tin.it
authors.forename: A
authors.initials: A
authors.lastname: Preti
mesh_terms: D000818:Animals; D014151:Anti-Anxiety Agents / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D001007:Anxiety / Q000188:drug therapy* / Q000523:psychology; D003346:Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D003521:Cyclopropanes / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D011687:Purines / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
chemical_list: D014151:Anti-Anxiety Agents; D003521:Cyclopropanes; D011687:Purines; C452867:SV-030; D003346:Corticotropin-Releasing Hormone